AveXis — Corporate Update (April 2017)
23 slides from AveXis's corporate update, Apr 25, 2017
Slide 1: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical studies and clinical trials for AVXS-101, including statements regarding the timing of initiation of studies or trials and related preparato
Slide 2: Our Strategy
Our Strategy 3 Build pipeline of gene therapy treatments beyond SMA Expand development of AVXS-101 into SMA Type 2 Establish foundational presence in SMA Type 1 Vision: Leader in rare and life-threatening neurological genetic diseases Strategic Focus & Investment Time
Slide 3: Overview of SMA
Overview of SMA 4 SMA is a devastating orphan disease that results in motor neuron loss and progressive weakness; it is the most common genetic cause of infant death Incidence: ~1 in 10,000 live births Caused by reduced SMN (survival motor neuron) protein levels from loss of/defective SMN1 gene SMA
Slide 4: SMA Types: A Devastating Disease
SMA Types: A Devastating Disease 5 TYPE 1 TYPE 2 TYPE 3 TYPE 4 SMN2 Copy Number Two Three or Four Three or Four Four to Eight Onset Before 6 Months 6-18 Months Early childhood to early adulthood (juvenile) Adulthood (20s-30s) usually after 30 Incidence per Live Birth Approximately 60% Approximately
Slide 5: Natural History of SMA Type 1
Natural History of SMA Type 1 “floppy baby” syndrome muscle weakness (legs more than arms) poor head control belly breathing bulbar muscle weakness (weak cry, difficulty swallowing, aspiration) will never sit unsupported loss of motor function: NeuroNEXT -- CHOP INTEND decrease of 10.5 points/yr. PN
Slide 6: Children Do Not Reach Any Major Motor Milestones
Children with SMA Type 1 Do Not Reach Any Major Motor Milestones Retrospective Study from large multi-center datasets (US and EU) Patients (n=33) have genetically confirmed homozygous deletion of exon 7 in SMN1 gene; categorized according to Dubowitz’s decimal classification (confirmation of SMN1 st
Slide 7: AVXS-101 Targets the Primary SMN Gene
AVXS-101 Targets the Primary SMN Gene 8 NORMAL INDIVIDUAL SMA-AFFLICTED INDIVIDUAL SMA-AFFLICTED INDIVIDUAL TREATED WITH AVXS-101 SMN Genes SMN Protein SMN1 Primary SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up AVXS-101 Primary Functional SMN Protein No
Slide 8: Our Solution: AVXS-101 An Innovative Treatment Approach for SMA
Our Solution: AVXS-101 An Innovative Treatment Approach for SMA 9 scAAV ITR Continuous Promoter Human SMN Transgene scAAV ITR KEY COMPONENTS PURPOSE Recombinant AAV9 Capsid Shell Ability to deliver across the blood brain barrier (BBB) and into the spinal cord - Avoids the need for intrathecal delive
Slide 9: Clinical Study Closeout – January 20, 2017
Clinical Study Closeout – January 20, 2017 10 TRIAL OVERVIEW Route of Administration One-time intravenous infusion through peripheral limb vein Prednisolone 1 mg/kg 1 day Pre-GT Trial Design Open-label, dose-escalation scAAV9.CB.SMN Principal Investigator Jerry R. Mendell, M.D. AVXS-101 PHASE 1 TRIA
Slide 10: Event-Free Survival Data – January 20, 2017
Event-Free Survival Data – January 20, 2017 11 * A month is defined as 30 days Cohort 1 6.7E13 vg/kg sc.AAV9.CB.SMN Cohort 2 2.0E14 vg/kg sc.AAV9.CB.SMN PNCR (Finkel) 2014 Natural History Study: 75% event-free 50% event-free 25% event-free 8% event-free Age at Last Follow-up Cohort 1*: 30.8 months (
Slide 11: CHOP INTEND vs. Age – January 20, 2017
CHOP INTEND vs. Age – January 20, 2017 12 COHORT 1 (n=3) Baseline Age (months): 5.9 [median], 6.3 [mean] Current Age (months): 30.8 [median], 30.4 [mean] Mean CHOP INTEND Increase: 7.7 points COHORT 2 (n=12) Baseline Age (months): 3.1 [median], 3.4 [mean] Current Age (months): 20.2 [median], 20.7 [m
Slide 12: Nutritional and Respiratory Supportive Care
Finkel et al. Observational Study of Spinal Muscular Atrophy Type I and Implications for Clinical Trials. Neurology. August 2014. SMA Type 1 Children Typically Require Significant Nutritional and Respiratory Supportive Care By 12 Months Of Age Nearly all Type 1 patients require nutritional support b
Slide 13: Safety and Tolerability Observations
SAFETY AND TOLERABILITY OBSERVATIONS No new treatment-related SAEs or AEs observed As previously reported, a total of 5 treatment-related AEs in 4 patients have been reported following monitoring and source verification Treatment-related SAEs and AEs were clinically asymptomatic elevated liver funct
Slide 14: Children Who Never Sit Unassisted
Children with SMA Type 1 Never Sit Unassisted 15 DISEASE CHARACTERISTICS Disease onset <6 months Hypotonia and weakness Bulbar muscle weakness Difficulty breathing and swallowing Inexorable progression to nutritional failure Inexorable progression to respiratory failure DEVELOPMENTAL MILESTONE PROGN
Slide 15: Motor Milestone Achievements in Cohort 2
Motor Milestone Achievements in Cohort 2 16 Cohort 2 2.0e14 vg/kg Age at GT (mos) Motor Milestone Achievement Brings hand to mouth Head control Partial Rolla Rollb Sitting with assistance Sitting Unassisted ≥ 5 secondsc ≥ 10 secondsd ≥ 30 secondse E.04 6 E.05 4 E.06 2 E.07 4 E.08 8 E.09 5 E.10 1 E.1
Slide 16: Cohort Achieved Motor Milestones Not Seen in the Natural History
Cohort 2 Achieved Motor Milestones Not Seen in the Natural History of SMA Type 1 17
Slide 17: ICV and CSF Delivery Preclinical Studies
AVXS-101 was delivered via Intracerebroventricular (ICV) injection in the mouse model for SMA (SMND7 mouse) to evaluate phenotypic rescue The scAAV9-Green Fluorescent Protein (scAAV9-GFP) was used to evaluate transgene/AAV9-biodistribution and was delivered via ICV injection in mice and intrathecal
Slide 18: Pre-existing Anti-AAV9 Antibody Experience
Most patients (13/16) did not exhibit elevated antibody titers prior to gene replacement therapy Consistent with the literature, AAV9 antibody seropositivity under the age of 10 appears rare When positive in young children, titers are typically low AAV9 seropositivity increases after age 40, especia
Slide 19: Most of Cohort 2 Achieved Ability to Sit Unassisted
Regardless of age at dosing and baseline motor function, most of Cohort 2 has achieved the ability to sit unassisted In Cohort 2 (proposed therapeutic dose), 11/12 patients have surpassed a CHOP-INTEND score of 40, 10/12 have surpassed a score of 50, and 2/12 have achieved the max score Natural Hist
Slide 20: All patients alive and ≥15 months of age
All patients are alive and ≥15 mos of age (6 are >2 years old) All patients reached 13.6 months of age free of permanent ventilation The published natural history shows that only 25% of SMA Type 1 patients survive to 13.6 months of age without permanent ventilation 9 of 12 patients in Cohort 2 sat u
Slide 21: Company Milestones
Company Milestones 22 Type 1 Program Type 2 Program 2017 Manufacturing Q2 2017: Initiate SMA Type 1 pivotal trial in U.S.* Q1 2017: Provide update on EU regulatory pathway and trial design feedback Q2 2017: Anticipated update/minutes from CMC Type B meeting Q1 2017: 13.6 months of data for all patie
Slide 22: Company Milestones
Company Milestones
Slide 23: Thank You
Thank You aveRis